The Adenocarcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adenocarcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adenocarcinoma and features dormant and discontinued products.
GlobalData tracks 98 drugs in development for Adenocarcinoma by 89 companies/universities/institutes. The top development phase for Adenocarcinoma is phase i with 35 drugs in that stage. The Adenocarcinoma pipeline has 84 drugs in development by companies and 14 by universities/ institutes. Some of the companies in the Adenocarcinoma pipeline products market are: Eisai, Innovent Biologics and Pfizer.
The key targets in the Adenocarcinoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Tubulin , and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1).
The key mechanisms of action in the Adenocarcinoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with eight drugs in Phase II. The Adenocarcinoma pipeline products include 14 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Adenocarcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Adenocarcinoma overview
Adenocarcinoma is a type of cancer that starts in mucus-producing (glandular) cells. Many organs have these types of cells and adenocarcinoma can develop in any of these organs. The symptoms of adenocarcinoma will depend on which organ is affected by cancer. The patients may not experience any symptoms until the cancer is more advanced.
For a complete picture of Adenocarcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
